Curriculum Vitae For:
Christopher Paul Steidle,
M.D.
Northeast Indiana Research,
LLC
7900 West Jefferson Blvd.,
Suite # 301
Fort Wayne, Indiana 46804
Research Office Phone: (219) 434-1939
Research Office Fax: (219) 434-1418
Research E-Mail Address: csteidle@americasdoctor.com
Education: 1979-1983 Doctor
of Medicine, University of Virginia School of
Medicine
1975-1979
B.S.,
Parasitology, Tulane University, New Orleans,
Louisiana (Magna Cum Laude)
Work Experience:
1989-Present Northeast Indiana Urology, P.C.
1985-1989
Residency
and Chief Residency in Urology, Indiana University Hospitals, Department of
Urology, Indianapolis, IN
1984-1985
Surgical
Residency, Indiana University Hospitals, Department of Surgery Indianapolis, IN
1983-1984
Surgical
Internship, Indiana University Hospital, Department of Surgery, Indianapolis,
IN
1980 National Institute of Health Training Fellowship; Tumor
Biology, Department of Otolaryngology, University of Virginia School of
Medicine, Charlottesville, VA
Board
Certification: American Board
of Urology, 1991, 1999
Hospital Affiliations:
1989-Present Parkview Memorial Hospital, Fort
Wayne, Indiana
1989-Present Veterans Administration Hospital,
Fort Wayne, Indiana
1989-Present Whitley County Memorial Hospital, Columbia
City, Indiana
1989-Present St. Joseph Medical Center, Fort Wayne, Indiana
1989-Present Lutheran Hospital of Indiana, Fort
Wayne, Indiana
1989-Present Kosciusko Community Hospital,
Warsaw, Indiana
1989-Present Rehabilitation Hospital of Fort
Wayne, Fort Wayne, Indiana
1989-Present Huntington Memorial Hospital,
Huntington, Indiana
2000-Present Dupont Surgery Center, Fort Wayne, Indiana
Revised February 23, 2001 page 1
Curriculum Vitae For:
Christopher Paul Steidle,
M.D.
Professional Affiliations:
Allen
County Cancer Services Board of Trustees
American Urology Association
North Central Section – American Urology Association
Clinical Associate Professor of Urology-Indiana
University School of
Medicine, Fort Wayne,
Indiana
Honors and Awards:
1989 American College of
Surgeons-Carl H. McCaskey Award
1998-1999 Best
Doctors of America
Research:
1.
A
Double-Blind, Placebo-Controlled, Dose-Ranging, Clinical Evaluation of XXX And
XXX Subjects With Benign Prostatic Hyperplasia.
2.
A Randomized, Multi-Center, Double-Blind,
Double Dummy, Comparative Trial of XXX And XXX The Treatment Of Bacterial
Prostatitis
3.
A Randomized, Prospective Study Comparing
Intermittent Versus Continuous XXX Deprivation With XXX Depot In Clinical Stage
D2 Prostate Cancer.
4.
A
Phase II Study: Intravesical XXX In Patients With Transitional Cell Carcinoma
Of The Bladder.
5.
A
Phase II Study: Intravesical XXX In Patients With Carcinoma Is Situ Of The Bladder
Who Have Failed Or Have Recurrence Following Treatment With XXX.
6.
A
Phase II Clinical Trial To Assess Efficacy And Safety of XXX In Patients With
Hormone-Refractory Stage D2 Prostate Cancer.
7.
A
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose,
Multi-Center Study To Assess The Efficacy And Safety Of XXX Administered Over
Six Months To Male Subjects With Erectile Dysfunction.
8.
A
Randomized, Double-Blind, Multi-Center Trial Comparing XXX And XXX For The
Treatment Of Complicated Urinary Tract Infections.
9.
An
Open-Label, Non-Comparative Study To Assess The Long-Term Safety of XXX In
Patients With Erectile Dysfunction.
Revised February 23, 2001 page 2
Curriculum
Vitae For:
Christopher
Paul Steidle, M.D.
10.
A
Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study Of XXX
In Patients With Recurrent Genital Herpes.
11.
A
Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study Of XXX
In Patients With Recurrent Herpes Labialis.
12.
A
Randomized, Double-Blind, Multi-Center, Phase II/III Comparison Of Two Dose
Regimens of XXX To XXX In The Treatment Of Women With Acute Uncomplicated
Urinary Tract Infection.
13.
An
Open-Label, Non-Comparative Extension Study of XXX In Patients With Erectile
Dysfunction.
14.
Multi-Center,
Double-Blind, Placebo-Controlled, Randomized, Follow-Up Study Of The Efficacy
And Safety Of An Infusion Of XXX 2, 4, 6 Mg Given As Required (Maximum
Frequency Every 2 Weeks), For 6 Months, In Patients With Prostate Cancer And
Bone Metastases.
15.
A
Phase III, Efficacy And Safety Study Of Four Fixed Doses Of XXX Versus Placebo
In The Treatment Of Male Erectile Dysfunction.
16.
A
Phase III, Long-Term, Open-Label, Flexible-Dose Efficacy And Safety Study Of
XXX In The Treatment Of Male Erectile Dysfunction.
17.
Efficacy
And Safety Study Of XXX And XXX In Middle-Aged And Elderly Women With Urinary
Incontinence.
18.
An
International Phase II, Randomized, Double-Blind, Multi-Center Study To
Determine The tolerability And Efficacy Of Three Different Doses Of XXX In
Patients With Rising Prostate Specific Antigen Levels After Definitive
Treatment.
19.
A
Randomized, Double-Blind, Multi-Center, Phase II/III, Comparison Of Two Dose
Regimens Of XXX To XXX In The Treatment Of Women With Acute Uncomplicated
Urinary Tract Infection.
20.
A
Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Twenty-One Days
Of Once Daily Treatment With An Investigational Drug In Patients With Mild To
Moderate Erectile Dysfunction.
21.
XXX
For Urinary Incontinence: A Multiple-Dose Study For Efficacy And Safety.
22.
A
Placebo-Controlled, Parallel-Group, Crossover Design Phase III Trial Of XXX In
Patients With Erectile Dysfunction.
Revised February 23, 2001 Page 3
Curriculum Vitae For:
Christopher Paul Steidle,
M.D.
23.
An
Randomized, Double-Blind, Multi-Center, Phase II/III Comparison Of XXX To XXX
In The Treatment Of Complicated Urinary Tract Infection And Pyelonephritis.
24.
Part
A: Clinical Efficacy And Safety Of XXX Compared To XXX And Placebo – A Phase
III, Randomized Double-Blind, Multi-National Study In Patients With Detrusor
Overactivity And Symptoms Of Frequency, Urge Incontinence And Urgency.
Part B: Long-Term Safety, Tolerability And Clinical
Efficacy Of XXX In Patients With Detrusor Overactivity And Symptoms Of
Frequency, Urge Incontinence And Urgency.
25.
Long-Term
Safety, Tolerability And Clinical Efficacy Of XXX. A Phase III, Open-
Label, Multi-National Study In Patients With Detrusor Overactivity,
Symptoms Of Frequency, Urge Incontinence And/Or Urgency.
26.
An
Open-Label, 24 Month Trial Of XXX In Patients With Minimal Erectile
Dysfunction.
27.
An
Open-Label, 12 Month Trial Of XXX In Patients With Mild To Moderate Erectile
Dysfunction.
28.
A
Comparative Study Of The Clinical Efficacy Of Two Dosing Regimens Of XXX.
29.
A
Repeated-Dose Evaluation Of Analgesic Use And Safety Of XXX In Patients With
Chronic Cancer Pain.
30.
The
Use Of XXX Device In Female Urinary Incontinent Patients.
31.
Safety
And Tolerability Of Long-Term Administration Of XXX.
32.
A
Repeated-Dose Evaluation Of Analgesic Use And Safety Of XXX In Patients With
Chronic Non-Malignant Pain.
33.
A
Multi-Center, Open-Label, Dose Escalation Study Of The Safety And Therapeutic
Effects Of XXX Administered As An Intramuscular (IM) Or Subcutaneous (SC)
Injection, In Prostate Cancer Patients Who Are Candidates For Initial Hormonal
Therapy.
34.
A
Phase II, Multi-Center, Open-Label Study Of XXX Administered As A Subcutaneous,
Continuous Infusion For 57 To 85 Days (8 To 12 Weeks) In Patients Undergoing
Radiation Therapy Interstitial Seen Implantation Or Other Radiation Therapy.
Revised February 23, 2001 Page 4
Curriculum Vitae For:
36. An Extension Study To Evaluate The Safety And Tolerability Of XXX In Subjects With Hormone Refractory Adencarcinoma Of The Prostate.
37.
A
Clinical Evaluation Of XXX For Urinary Incontinence.
38.
A
Three Month, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study
Assessing The Efficacy And Safety Of XXX In Patients With Symptomatic Benign
Prostatic Hyperplasia.
39.
A
Phase IV Study Evaluating The Agonistic Stimulation Of XXX Following
Reinjection With XXX 3-Month 22.5 Mg And XXX 7.5 Mg And Assessment Of The
Pharmacokinetic/Pharmacodynamic Relationship For XXX 22.5 Mg.
40.
A
Methodlogy Trial To Assess The Reproducibility Of Noninvasive Measurements Used
In The Diagnosis And Assessment Of Treatment Outcome For Subjects With Abnormal
Voiding.
41.
A
Randomized, Double-Blind, Comparative Trial Of XXX Versus Placebo In Patients
With Early Prostate Cancer.
42.
A
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose,
Multi-Center Study to Assess Efficacy and Safety of Daily Oral Administration
of XXXX versus Placebo in Male and Female Subjects with Overactive Bladder.
43.
Efficacy
and Safety of XXXX Compared with Placebo in Subjects with Stress Urinary
Incontinence.
44.
A
Phase II, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Twelve
Week Pilot Study to Evaluate the Safety and Efficacy of XXXX Administered with
Estrogen to Post-Menopausal Women.
45.
An
Evaluation on Effect of 20mg XXXX on Sperm Concentration in Normal Healthy
Subjects or Subject with Mild Erectile Dysfunction.
46.
A
Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of XXXX for
the Treatment of Male Erectile Dysfunction in an At-Home Setting.
47.
An
Open-Label, Continuation Trial of XXXX in Male Erectile Dysfunction Patients
Who Previously Participated in a Parent Study.
Revised: February 23, 2001 Page 5
Curriculum
Vitae For:
Christopher Paul Steidle,
M.D.
48.
A
Randomized, Double-Blind, Placebo-Controlled Study to Assess Duration of
Responsiveness to XXXX in Patients with Erectile Dysfunction.
49.
A
Randomized, Double-Blind, Crossover Study of XXXX Compared with XXXX for the
Treatment of Patients with Erectile Dysfunction.
1.
Steidle,
C.P. “The Impotence Sourcebook.” Lowell
House Anodyne Press. 1998
2.
Steidle,
C.P. “Calculus Disease of the Kidney and Bladder.” Clinical Practice of
Emergency medicine. A. Harwood-Nuss et.al. J.B. Lippincott. 1991.
3.
Steidle,
C.P. “Bladder Fistulae.” Surgical Management of Urologic Disease.
M.A. Droller (Ed). St. Louis:
Mosby Year Book. 1992.
4.
Steidle,
C.P. “ESWL Research II.” Urinary and Biliary Lithotripsy. New York:
Plenum Press. 1989.
5. Steidle, C.P. “Female Sexual Dysfunction” Wellness Web, www.wellweb.com. 2000
Articles
1.
Steidle,
C.P.: Effects of colchicine on the egglaying capability of Schistoma
mansoni. Honors Thesis. Tulane University, 1979.
2.
Thomalla,
J.V., Steidle, C.P., Leapman, S.B., et.al.: Ureteral obstruction of a renal
allograft secondary to Candida krusei. Transplantation Proceedings. 20: 551, 1988.
3.
Kennedy,
H.A., Steidle, C.P., Mitchell, M.E., et.al.:
Collateral urethral
duplication in the frontal
plane: A spectrum of cases. J. Urol., 139:32, 1988.
4.
Rowland,
R.G., Donohue, J.P., Kopecky, K.K., Steidle, C.P., et.al.: Correlation
of computed tomographic
changes and histologic findings in 80 patients having
RPLND after chemotherapy for
testis cancer. J. Urol., 136:1176,
1987.
5.
Steidle,
C.P., Kennedy, H.A., Mitchell, M.E., et.al.:
Sympheaseal diastasis in
absence of
exstropy-epispadias complex. J. Urol.,
140:349, 1988
6.
Bihrle,
R., Foster, R.S., Steidle, C.P., et.al.:
Creation of a transverse colon-gastric
composite reservoir: A new technique. J. Urol., 141:1217, 1989.
7.
Steidle,
C.P., Mulcahy, J.J.: Erosion of penile
prostheses-A complication of
urethral
catheterization. J. Urol., 142:176,
1989.
Revised February 23, 2001 Page 6
Curriculum Vitae For:
Christopher Paul Steidle,
M.D.
8.
Steidle,
C.P., Cohen, M.D., Hoover, D.M., et.al.:
Comparative contractile
response among ventral,
dorsal and lateral lobes of the rat prostate.
The Prostate.
15:53, 1989.
9.
Steidle,
C.P., Cohen, M.L., Neubauer, B.L.:
Bradykinin induced contractions of
canine prostate and bladder
effect of angiotensin converting enzyme inhibition.
J. Urol., 144:390, 1990.
10.
Hockley,
N.K.M., Steidle, C.P., West, K.W., Mitchell, M.E.: Ectopic ureter
presenting as a psoas
abscess. J. Urol., 143:xx, 1991.
11.
Hockley,
N.K.M, Foster, R.S., Bihrle, R., Steidle, C.P., et.al.: Use of magnetic
resonance imaging to
determine surgical approach of renal cell carcinoma with
vena cave extension. Urology, 36:55, 1990.
12.
Kopecky,
K.K., Steidle, C.P., Eble, J.N., et.al.:
Endoluminal radio-frequency
electrocautery for permanent
ureteral occlusion of swine. Radiology,
170:1043,
1989.
13.
Bihrle,
R., Klee, L., Adams, M.C., Steidle, C.P., et.al.: Transverse colon-gastric
composite reservoir. Urology, 37:36, 1991.
14.
Jones,
J., Lingeman, J.L., Steidle, C.P.: The
roles of ESWL and PCNL in the
management of pyelocalieal
diverticula. J. Urol., 146:724, 1991.
15.
Hegland,
A., Steidle, C.P.: Stopping
incontinence at the source.
Contemporary
Long Term Care. December, 1990, page 48.
16.
Kennedy,
K.L., Steidle, C.P.: Achieving a state
of urinary incontinence for
residents of nursing
facilities part I: The history and
physical examination.
Ostomy/Wound Management,
35:72, 1991.
17.
Steidle,
C.P., Kennedy, K.L.: Achieving a state
of urinary incontinence for
residents of nursing
facilities part II: Urodynamics and
laboratory investigation.
Ostomy/Wound Management,
36:45, 1991.
18.
Steidle,
C.P., Kennedy, K.L.: Achieving a state
of urinary incontinence for
residents of nursing
facilities part III: Manufactured
incontinence. Ostomy/
Wound Management, 36:36,
1992.
19. Steidle, C.P., Stone, A., Boyd, S., Mulcahy,
J.J.: Implanting an AMS Sphincter
800 Urinary Prosthesis after failed collagen
injections. Colleagues in Urology,
11:xxx, 1994.
Revised February 23, 2001 Page 7
Curriculum Vitae For:
Christopher Paul Steidle,
M.D.
20.
Kaefer,
M., Audia, N., Bruchovsky, R.L., Goode, R.L., Hsiao, K.C., Leibovitch,
I.Y., Kruschinski, J.H., Lee, C., Steidle, C.P.,
Sutkowski, D.M., Neubauer, B.L.:
Characterization of type 1 5 alpha-reductase activity in human DU-145
human prostate adenocarcinoma cells.
The Journal of Steroid Biochemistry and Molecular Biology. In Press.
21.
Newman,
D.K., Steidle, C.P., Wallace, D.: The
assessment and management of
Urinary incontinence. Managed Care. In Press
22.
Kennedy,
K.L., Steidle, C.P., Letizia, T.:
Urinary incontinence: the
basics. Ostomy/Wound
Management. In Press.
23.
Goldstein,
I., Lue, Tom F., Padma-Nathan, Harin, et al:
Oral Sildenafil In The Treatment Of Erectile Dysfunction. The New
England Journal Medicine 338:1397-1404
24.
Steidle,
C.P.: Terazosin and The Study of
BPH. The New England Journal Medicine
January 1995
___________________________________ ____________________
Christopher Paul Steidle, M.D. Date
Revised February 23, 2001 Page 8